细胞死亡调节因子GRIM-19蛋白在肾脏透明细胞癌组织中的表达及意义

目的：探讨细胞死亡调节因子（GRIM-19）蛋白在肾脏透明细胞癌组织和正常肾组织中的表达及意义，阐明GRIM-19在肾脏透明细胞癌发生发展中的抑癌作用。方法： 采用免疫组织化学染色方法检测21例肾脏透明细胞癌组织和7例正常肾组织GRIM-19蛋白的表达；RT-PCR方法检测4例正常肾组织和8例肾脏透明细胞癌组织中GRIM-19基因mRNA的表达。结果： 免疫组化检测GRIM-19蛋白在肾脏透明细胞癌组织中阳性表达率为52.3%（11/21），在正常肾脏组织的阳性表达率为100%（7/7），两者比较差异有显著性（P<0.05）。病理分级Ⅰ、Ⅱ和Ⅲ级的肾脏透明癌组织中的表达率分别为100%（6/6）、40%（4/10）和20%（1/5），三种病理分级GRIM-19表达率比较差异有显著性（P<0.01）。RT-PCR检测GRIM-19基因在肾脏透明细胞癌组织中阳性表达率为62.5%（5/8），在正常肾脏组织的阳性表达率为100%（4/4），两者比较差异有显著性（P<0.01）。结论：GRIM-19在肾脏透明细胞癌基因和蛋白水平表达明显下降，并与其病理分级存在明显的关联性，提示GRIM-19蛋白可能在肾脏透明细胞癌发生发展中发挥抑癌作用。

Expression of cell death regulatory gene GRIM-19 in human renal clear cell carcinoma tissue and its significance

Objective To explore the expression of cell death regulatory gene GRIM-19 in human renal clear cell carcinoma tissues and normal renal tissues and significance,and clarity the effect of GRIM-19 in the process of renal clear cell carcinoma.Methods The expressions of GRIM-19 were studied by means of immunohistochemistry in 21 renal clear cell carcinoma tissues and 7 normal renal tissues.RT-PCR was used to detect the mRNA levels of GRIM-19 in 4 normal renal tissues and 8 renal clear cell carcinoma tissues.Results The results of immunohistochemistry indicated that the positive rates of GRIM-19 were 52.3%(11/21)and 100%(7/7) in renal clear cell carcinoma tissues and normal renal tissues,the difference was significant(P<0.05).The positive rates of GRIM-19 were 100%(6/6),40%(4/10)and 20%(1/5)in the grade Ⅰ,Ⅱand Ⅲ of renal clear cell carcinoma,the differences between them were significant(P<0.01).RT-PCR results indicated that the positive rates of GRIM-19 were 62.5%(5/8)and 100%(4/4)in renal clear cell carcinoma tissues and normal renal tissues,the difference between them was significant(P<0.01).Conclusion The expression of GRIM-19 obviously decrease in renal clear cell carcinoma tissue in the levels of gene and protein and the decreasing exists relevance with the grade of pathology.It indicates that GRIM-19 expression may be play an important role in the progress of renal clear cell carcinoma.